Combination pharmacologic therapies for heart failure: What next after angiotensin-converting enzyme inhibitors and beta-blockers?
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Although the introduction of angiotensin-converting enzyme (ACE) inhibitors and β-adrenergic blockers has resulted in significant improvements in the management of heart failure (HF), morbidity and mortality remain high. Therefore, additional approaches have been sought to discover newer agents that might add incremental benefit. Although not all of these approaches have been successful, there have been some notable new approaches to therapy that have shown benefit or may be promising in terms of additional benefit. Most of these agents are targeted to achieve a more global neurohormonal blockade aiming to reduce or potentially reverse the ventricular remodeling process that occurs in HF. Some of the newer approaches aim for targets other than neurohormonal systems, eg, effects on myocardial metabolism or the vasculature. This article reviews the latest advances in pharmacologic therapy in HF, looking at several trials that may have a significant impact on the treatment of HF. We also discuss several newer agents with promising potential in HF management.
- Young JB: The global epidemiology of heart failure. Med Clin North Am 2004, 88:1135–1143. This article addresses the tremendous challenges associated with the increasing prevalence, economic burden, and morbidity associated with HF. CrossRef
- American Heart Association. Heart Disease and Stroke Statistics-2005 Update. Dallas, TX: American Heart Association; 2005.
- Jessup M, Brozena S: Heart failure. N Engl J Med 2003, 348:2007–2018. CrossRef
- Cohn JN, Tognoni G: A randomized trial of the angiotensinreceptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345:1667–1675. This trial studied the efficacy of valsartan in HF, and although there was no reduction in mortality, hospitalization rates were reduced significantly. CrossRef
- Young JB, Dunlap ME, Pfeffer MA, et al.: Mortality and morbidity reduction with candesartan in patients with chronic heart failure. Circulation 2004, 110:2618–2626. The CHARM Low EF Trials studied the efficacy of candesartan in HF with EF less than 40%, demonstrating significant reduction in cardiovascular mortality and HF hospitalization rates. CrossRef
- Yusuf S, Pfeffer MA, Swedberg K, et al.: Effects of candesartan in patients with chronic heart failure and preserved left ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003, 362:777–781. CrossRef
- Pfeffer MA, McMurray JV, Vellazquez EJ, et al.: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003, 349:1893–1906. CrossRef
- Jessup M: Aldosterone blockade and heart failure. N Engl J Med 2003, 348:1380–1382. CrossRef
- Weber KT: Aldosterone in congestive heart failure. N Engl J Med 2001, 345:1689–1697. CrossRef
- Struthers AD: Impact of aldosterone on vascular pathophysiology. Congest Heart Fail 2002, 8:18–22.
- Francis J, Weiss RM, Felder RB, et al.: Central mineralocorticoid receptor blockade improves volume regulation and reduces sympathetic drive in heart failure. Am J Physiol Heart Circ Physiol 2001, 281:H2241-H2251.
- Francis J, Beltz T, Johnson AK, Felder RB: Mineralocorticoids act centrally to regulate blood-borne tumor necrosis factor-alpha in normal rats. Am J Physiol Regul Integr Comp Physiol 2003, 285:R1402-R1409.
- Pitt B, Zannand F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709–717. RALES studied the effect of spironolactone in HF and demonstrated a dramatic reduction in mortality in patients with NYHA class IV (current or recent) HF. CrossRef
- Cicoria M, Zanolla L, Rossi A, et al.: Long term dose dependent effects of spironolactone on left ventricular and exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol 2002, 40:304–310. CrossRef
- Pitt B, Remme WJ, Zannad F, et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309–1321. CrossRef
- Hunt SA, Baker DW, Chin MH, et al.: ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: executive summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): Developed in collaboration with the International Society for Heart and Lung Transplantation; endorsed by the Heart Failure Society of America. Circulation 2001, 104:2996–3007.
- Juurlink DN, Mamdani MM, Lee DS, et al.: Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med 2004, 351:543–551. CrossRef
- Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT). http://ClinicalTrials. gov/ct/show/nct00094302. Accessed April 9, 2005.
- Cohn JN, Archibald DG, Ziesche S, et al.: Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986, 314:1547–1552. This early V-HeFT I study demonstrated the beneficial effects of adding the combination of hydralazine and nitrates to digitalis and diuretics in patients with HF. CrossRef
- Carson P, Ziesche S, Johnson G, Cohn JN: Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail 1999, 5:178–187. CrossRef
- Yancy CW: Heart failure in African Americans: a cardiovascular enigma. J Card Fail 2000, 6:183–186. CrossRef
- Khan D, Duff SJ, Tomasian D, et al.: Effects of black race on forearm resistance vessel function. Hypertension 2002, 40:195–201. CrossRef
- Taylor AL, Ziesche S, Yancy C, et al.: Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004, 351:2049–2057. The recent A-HeFT trial evaluated the combination of hydralazine and isosorbide dinitrate in black patients with HF. The results demonstrated significant reductions in mortality and morbidity, with improved quality of life in the treatment group. CrossRef
- Gheorghiade M, Gattis W, O’Connor CM: Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure. JAMA 2004, 291:1963–1971. CrossRef
- Torre-Amione G, Young JB, Durand JB, et al.: Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III and IV congestive heart failure. Circulation 2001, 103:973.
- O’Connor CM, Gattis WA, Adams KF Jr, et al.: Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous Tezosentan Study (RITZ-4). J Am Coll Cardiol 2003, 41:1452–1457. CrossRef
- Lopaschuk GD, Rebeyaka IM, Allard MF: Metabolic modulation-a means to mend a broken heart. Circulation 2002, 105:140–142.
- Chaitman BR, Pepine CJ, Parker JO, et al.: Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 2004, 291:309–316. CrossRef
- Chandler MP, Stanley WC, Morita H, et al.: Short-term treatment with ranolazine improves mechanical efficiency in dogs with chronic heart failure. Circ Res 2002, 91:278–280. CrossRef
- Combination pharmacologic therapies for heart failure: What next after angiotensin-converting enzyme inhibitors and beta-blockers?
Current Heart Failure Reports
Volume 2, Issue 2 , pp 89-93
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links
- Industry Sectors